Drugs / BODITRECTINIB
BODITRECTINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04014257 | Aug 2019 → Jan 2021 | cancer | Handok Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BODITRECTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314454 ↗ |
| Known as | AUM-601 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314454 ↗ |
| Known as | CHC2014 | “A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies” NCT04014257 ↗ |
| Known as | HL-5101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314454 ↗ |
| Known as | NOV1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04014257 ↗ |
| Action | Inhibit | “a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A(TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor...” NCT04014257 ↗ |
| Modality | Small molecule | — CHEMBL5314454 ↗ |